NCT04488003: A trial that was reported late by BioMed Valley Discoveries, Inc
This trial has reported, although it was 7 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04488003 |
|---|---|
| Title | A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 7, 2021 |
| Completion date | Feb. 15, 2023 |
| Required reporting date | Feb. 15, 2024, midnight |
| Actual reporting date | Feb. 22, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 7 |